Abstract
AbstractPotential synergism between Bruton’s tyrosine kinase (BTK) inhibitor and lenalidomide in treating aggressive B-cell lymphoma has been suggested. Here, the authors report a single-arm phase II clinical trial of combination of acalabrutinib, lenalidomide and rituximab (R2A) in patients with aggressive relapsed/refractory aggressive (R/R) B-cell non-Hodgkin lymphoma (NHL). The primary endpoint of this study is objective response rate (ORR), and the secondary endpoints are complete remission (CR) rate, duration of response (DoR), progression-free survival (PFS) and overall survival (OS). A total of 66 patients are enrolled mostly with diffuse large B-cell lymphoma. The ORR is 54.5% and CR rate is 31.8% meeting the primary end point. The median DoR is 12.9 months, and 1-year PFS and OS rate is 33.1% and 67.5% respectively. Adverse events (AE) are manageable with the most frequent AE being neutropenia (31.8%). Patients with MYD88 mutations, subtypes known for NF-κB activation, and high BTK expression by immunohistochemistry respond well. Overall, these results show a significant efficacy of the R2A regimen in patients with aggressive R/R B-cell NHL, with exploratory biomarkers suggesting potential associations with response. (ClinicalTrials.gov 51 identifier: NCT04094142)
Funder
AstraZeneca Korea
Celltrion Healthcare Co., Ltd Samyang Holdings
Publisher
Springer Science and Business Media LLC
Reference39 articles.
1. Dotan, E., Aggarwal, C. & Smith, M. R. Impact of rituximab (rituxan) on the treatment of B-cell Non-Hodgkin’s lymphoma. PT 35, 148–157 (2010).
2. Coiffier, B. et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N. Engl. J. Med. 346, 235–242 (2002).
3. Friedberg, J. W. Relapsed/refractory diffuse large B-cell lymphoma. Hematol. / Am. Soc. Hematol. Educ. Program 2011, 498–505 (2011).
4. Hitz, F. et al. Outcome of patients with primary refractory diffuse large B cell lymphoma after R-CHOP treatment. Ann. Hematol. 94, 1839–1843 (2015).
5. Zelenetz, A. D., Gordon, L.I., Abramson, J. S. & Advani, R. H. NCCN Guidelines Version 1.2024; B-Cell Lymphomas. Natl. Compr. Cancer Netw. MS1-118 (2024).
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献